Abstract
tumor, tumors, pancreatic cancer, HER2‐positive urothelial bladder cancer
TUMOR, TUMORS, RECRUITMENT, PANCREATIC CANCER
The antibody‐drug conjugate trastuzumab emtansine (T‐DM1) is approved for human epidermal growth factor receptor 2 (HER2/The phase II KAMELEON study investigated the efficacy of T‐DM1 in selected HER2‐positive non‐breast tumors. Although KAMELEON was terminated prematurely due to recruitment difficulty, the study demonstrated that patients with HER2‐positive urothelial bladder cancer or pancreatic cancer can respond to T‐DM1. This study provided insight into the prevalence of HER2 positivity and expression patterns in these tumor types and may inform the use of T‐DM1–based regimens in HER2‐positive non‐breast tumors.
